ERBB2 and gastric neoplasm: This is a selective HER2 TKI with reduced inhibition on EGFR that exhibited antitumor activity in breast and gastric tumors in preclinical models administered as a monotherapy [172] or in combination with trastuzumab in HER2+ breast cancer xenograft models [173].